The Durability Question: GLP-1s as Chronic Therapy

A quiet but consequential question hangs over GLP-1 medications: what happens when you stop? The answer shapes how to think about them, and it pushes against a common assumption that a course of treatment ends with a cure. For these drugs, the better mental model is chronic management.

The stopping problem

The trial data on this point are consistent. The clearest evidence comes from the STEP 1 extension study, published in Diabetes, Obesity and Metabolism in 2022 (Wilding and colleagues), which followed participants for a year after they stopped semaglutide 2.4 mg.

The pattern was unambiguous. Participants had lost a mean of 17.3% of body weight on semaglutide over 68 weeks (versus 2.0% on placebo). One year after withdrawal, they regained about two-thirds of that loss — 11.6 percentage points — leaving a net loss of roughly 5.6% from baseline. Cardiometabolic improvements drifted back toward baseline as well.

Verified takeaway: in the STEP 1 extension, people regained about two-thirds of their semaglutide-driven weight loss within a year of stopping. That is the expected behavior of a chronic-disease treatment, not a sign the drug stopped working.

The right comparison clarifies things. We do not expect blood pressure to stay low after stopping an antihypertensive, or cholesterol to stay down after stopping a statin. We treat those as ongoing therapies for ongoing conditions. GLP-1 medications, on current evidence, belong in that category far more than in the antibiotic category, where you finish the course and you are done.

Why the framing matters

Getting this framing right changes several things at once.

Practical implications

• Expectations. Patients and prescribers should plan around long-term use rather than a temporary intervention, where appropriate and tolerated.
• Access and cost. Chronic therapy raises real, unresolved questions about affordability and sustained access, which are genuine limitations, not footnotes.
• Off-ramps. Whether and how some people might taper, ideally alongside durable lifestyle change, is an active and not fully answered question.
• Judgment. Framing regain as personal failure is both inaccurate and counterproductive given what the biology shows.

There is also direct evidence that staying on the drug preserves the benefit. In the STEP 4 randomized trial (JAMA, 2021), people who continued semaglutide after an initial run-in lost further weight, while those switched to placebo regained a substantial share — reinforcing that the effect depends on continued treatment.

The honest unknowns

Several things remain genuinely uncertain. The very long-term safety and effectiveness of multi-decade use are still accumulating. Whether subsets of people can maintain results after stopping, and what distinguishes them, is not well characterized. And the durability picture may shift as newer and combination agents mature. These are open questions, and it is more honest to name them than to paper over them.

The takeaway

GLP-1 medications look much more like chronic therapies than short courses, and the weight regain seen after stopping is the predicted behavior of treating a chronic condition. The honest bottom line is that this reframing is the most important thing to internalize: think of these as ongoing management, with real open questions about long-term use, access, and who, if anyone, can eventually step down. Useful drugs, realistically framed.

Sources

• Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension (Diabetes, Obesity and Metabolism, 2022)
• Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: the STEP 4 Randomized Clinical Trial (JAMA, 2021)